Low-Level Laser Gets Closer Look as Pain Treatment

The recent FDA clearance of a low-level laser therapy device for “whole body” pain may be prompting some to take a closer look at LLLT as a treatment for a variety of musculoskeletal disorders. Erchonia Corp. announced in July that it had received Food and Drug Administration clearance to market its FX 635 low-level laser as a treatment for chronic, “whole body” musculoskeletal pain. The company, based in Melbourne, Florida, previously received FDA clearance to market the device for treatment of chronic low back and heel pain associated with plantar fasciitis. In res...